Influenza vaccination of pregnant women protects them over two consecutive influenza seasons in a randomized controlled trial

Eleonora Mutsaerts; Shabir A Madhi; Clare L Cutland; Stephanie Jones; Andrea Hugo; Siobhan Trenor; Florette K Treurnicht; Kerstin Klipstein-Grobusch; Adriana Weinberg; Marta C Nunes

doi:10.1080/14760584.2016.1192473

Influenza vaccination of pregnant women protects them over two consecutive influenza seasons in a randomized controlled trial

Eleonora Mutsaerts
, Shabir A Madhi
, Clare L Cutland
, Stephanie Jones
, Andrea Hugo
, Siobhan Trenor
, Florette K Treurnicht
, Kerstin Klipstein-Grobusch
, Adriana Weinberg
, Marta C Nunes

Research output: Contribution to journal › Article › Academic › peer-review

2 Downloads (Pure)

Abstract

BACKGROUND: We assessed the persistence of hemagglutinin inhibition (HAI) antibodies and the vaccine efficacy (VE) of trivalent inactivated influenza vaccine (IIV3) following vaccination of a cohort of pregnant South African women during a second influenza season.

METHODS: A cohort of w omen, who participated in a randomized placebo-controlled trial on the safety, immunogenicity and efficacy of IIV3 in 2011 had HAI titers measured in 2012 and were monitored for influenza illness until the end of 2012.

RESULTS: The proportion of women with HAI titers ≥1:40 was significantly greater in vaccinees (63%) compared to placebo-recipients (22%; p<0.001). VE in 2012 was 63.8% (95% confidence interval [95%CI]: -33.7%, 90.2%); combined VE for 2011 and 2012 was 58.3% (95%CI: 0.2%, 82.6%).

CONCLUSIONS: The majority of women who received IIV3 during pregnancy had HAI titers above the putative threshold for protection against influenza illness one year after vaccination and showed a trend towards protection against influenza disease.

Original language	English
Pages (from-to)	1055-1062
Journal	Expert Review of Vaccines
Volume	15
Issue number	8
DOIs	https://doi.org/10.1080/14760584.2016.1192473
Publication status	Published - 2016

Keywords

Influenza vaccine
efficacy
immunogenicity
maternal immunization

Access to Document

10.1080/14760584.2016.1192473

trialFinal published version, 1.29 MB

Cite this

Mutsaerts, E., Madhi, S. A., Cutland, C. L., Jones, S., Hugo, A., Trenor, S., Treurnicht, F. K., Klipstein-Grobusch, K., Weinberg, A., & Nunes, M. C. (2016). Influenza vaccination of pregnant women protects them over two consecutive influenza seasons in a randomized controlled trial. Expert Review of Vaccines, 15(8), 1055-1062. https://doi.org/10.1080/14760584.2016.1192473

@article{4fd4d063903c4e10af8754740f3a5d57,

title = "Influenza vaccination of pregnant women protects them over two consecutive influenza seasons in a randomized controlled trial",

abstract = "BACKGROUND: We assessed the persistence of hemagglutinin inhibition (HAI) antibodies and the vaccine efficacy (VE) of trivalent inactivated influenza vaccine (IIV3) following vaccination of a cohort of pregnant South African women during a second influenza season.METHODS: A cohort of w omen, who participated in a randomized placebo-controlled trial on the safety, immunogenicity and efficacy of IIV3 in 2011 had HAI titers measured in 2012 and were monitored for influenza illness until the end of 2012.RESULTS: The proportion of women with HAI titers ≥1:40 was significantly greater in vaccinees (63\%) compared to placebo-recipients (22\%; p<0.001). VE in 2012 was 63.8\% (95\% confidence interval [95\%CI]: -33.7\%, 90.2\%); combined VE for 2011 and 2012 was 58.3\% (95\%CI: 0.2\%, 82.6\%).CONCLUSIONS: The majority of women who received IIV3 during pregnancy had HAI titers above the putative threshold for protection against influenza illness one year after vaccination and showed a trend towards protection against influenza disease.",

keywords = "Influenza vaccine, efficacy, immunogenicity, maternal immunization",

author = "Eleonora Mutsaerts and Madhi, \{Shabir A\} and Cutland, \{Clare L\} and Stephanie Jones and Andrea Hugo and Siobhan Trenor and Treurnicht, \{Florette K\} and Kerstin Klipstein-Grobusch and Adriana Weinberg and Nunes, \{Marta C\}",

year = "2016",

doi = "10.1080/14760584.2016.1192473",

language = "English",

volume = "15",

pages = "1055--1062",

journal = "Expert Review of Vaccines",

issn = "1476-0584",

publisher = "Taylor and Francis Ltd.",

number = "8",

}

TY - JOUR

T1 - Influenza vaccination of pregnant women protects them over two consecutive influenza seasons in a randomized controlled trial

AU - Mutsaerts, Eleonora

AU - Madhi, Shabir A

AU - Cutland, Clare L

AU - Jones, Stephanie

AU - Hugo, Andrea

AU - Trenor, Siobhan

AU - Treurnicht, Florette K

AU - Klipstein-Grobusch, Kerstin

AU - Weinberg, Adriana

AU - Nunes, Marta C

PY - 2016

Y1 - 2016

N2 - BACKGROUND: We assessed the persistence of hemagglutinin inhibition (HAI) antibodies and the vaccine efficacy (VE) of trivalent inactivated influenza vaccine (IIV3) following vaccination of a cohort of pregnant South African women during a second influenza season.METHODS: A cohort of w omen, who participated in a randomized placebo-controlled trial on the safety, immunogenicity and efficacy of IIV3 in 2011 had HAI titers measured in 2012 and were monitored for influenza illness until the end of 2012.RESULTS: The proportion of women with HAI titers ≥1:40 was significantly greater in vaccinees (63%) compared to placebo-recipients (22%; p<0.001). VE in 2012 was 63.8% (95% confidence interval [95%CI]: -33.7%, 90.2%); combined VE for 2011 and 2012 was 58.3% (95%CI: 0.2%, 82.6%).CONCLUSIONS: The majority of women who received IIV3 during pregnancy had HAI titers above the putative threshold for protection against influenza illness one year after vaccination and showed a trend towards protection against influenza disease.

AB - BACKGROUND: We assessed the persistence of hemagglutinin inhibition (HAI) antibodies and the vaccine efficacy (VE) of trivalent inactivated influenza vaccine (IIV3) following vaccination of a cohort of pregnant South African women during a second influenza season.METHODS: A cohort of w omen, who participated in a randomized placebo-controlled trial on the safety, immunogenicity and efficacy of IIV3 in 2011 had HAI titers measured in 2012 and were monitored for influenza illness until the end of 2012.RESULTS: The proportion of women with HAI titers ≥1:40 was significantly greater in vaccinees (63%) compared to placebo-recipients (22%; p<0.001). VE in 2012 was 63.8% (95% confidence interval [95%CI]: -33.7%, 90.2%); combined VE for 2011 and 2012 was 58.3% (95%CI: 0.2%, 82.6%).CONCLUSIONS: The majority of women who received IIV3 during pregnancy had HAI titers above the putative threshold for protection against influenza illness one year after vaccination and showed a trend towards protection against influenza disease.

KW - Influenza vaccine

KW - efficacy

KW - immunogenicity

KW - maternal immunization

U2 - 10.1080/14760584.2016.1192473

DO - 10.1080/14760584.2016.1192473

M3 - Article

C2 - 27212228

SN - 1476-0584

VL - 15

SP - 1055

EP - 1062

JO - Expert Review of Vaccines

JF - Expert Review of Vaccines

IS - 8

ER -

Influenza vaccination of pregnant women protects them over two consecutive influenza seasons in a randomized controlled trial

Abstract

Keywords

Access to Document

Fingerprint

Cite this